[Radionuclide synoviorthesis in hemophilia: experience in 107 patients]

Rev Med Chil. 2019 May;147(5):568-573. doi: 10.4067/S0034-98872019000500568.
[Article in Spanish]

Abstract

Background: In patients with hemophilia, radionuclide synoviorthesis, or the intra-articular injection of a radionuclide to decrease the synovial hypertrophy tissue, aims to decrease or avoid hemarthrosis.

Aim: To evaluate the effectiveness of radionuclide synoviorthesis in hemophilia.

Material and methods: Observational retrospective study of the evolution of 107 male patients aged 3 to 54 years who were subjected to radionuclide synoviorthesis between 2007 and 2015.

Results: Of 164 treated joints, in 65% treatment was successful, (defined as zero to two hemarthroses and absence of synovitis during the follow up period), in 17% it was partially successful (defined as two or less hemarthroses, but persistence of the synovitis) and failed in 18% of the procedures. No important complications were recorded.

Conclusions: Radionuclide synoviorthesis has an overall 82% success rate, is minimally invasive, can be used at any age and is inexpensive We recommend its implementation in Chilean hemophilia treatment centers.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Hemarthrosis / diagnostic imaging
  • Hemarthrosis / physiopathology
  • Hemarthrosis / therapy*
  • Hemophilia A / physiopathology
  • Hemophilia A / therapy*
  • Humans
  • Injections, Intra-Articular
  • Male
  • Middle Aged
  • Radioisotopes / administration & dosage*
  • Reproducibility of Results
  • Retrospective Studies
  • Rhenium / therapeutic use*
  • Synovitis / diagnostic imaging
  • Synovitis / physiopathology
  • Synovitis / therapy*
  • Time Factors
  • Treatment Outcome
  • Young Adult
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Radioisotopes
  • Yttrium Radioisotopes
  • Rhenium